Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials

Tina S. Skinner-Adams; Colin M. Stack; Katharine R. Trenholme; Chris L. Brown; Jolanta Grembecka; Jonathan Lowther; Artur Mucha; Marcin Drag; Pawel Kafarski; Sheena McGowan; James C. Whisstock; Donald L. Gardiner; John P. Dalton

doi:10.1016/j.tibs.2009.08.004

Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials

Tina S. Skinner-Adams
, Colin M. Stack
, Katharine R. Trenholme
, Chris L. Brown
, Jolanta Grembecka
, Jonathan Lowther
, Artur Mucha
, Marcin Drag
, Pawel Kafarski
, Sheena McGowan
, James C. Whisstock
, Donald L. Gardiner
, John P. Dalton

QIMR Berghofer Medical Research Institute
Griffith University
University of Western Sydney
University of Michigan Medical School
University of Edinburgh
Wroclaw University of Technology
Monash University
McGill University, Macdonald Campus

Research output: Contribution to a Journal (Peer & Non Peer) › Review article › peer-review

125 Citations (Scopus)

Abstract

The neutral aminopeptidases M1 alanyl aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) of the human malaria parasite Plasmodium falciparum are targets for the development of novel anti-malarial drugs. Although the functions of these enzymes remain unknown, they are believed to act in the terminal stages of haemoglobin degradation, generating amino acids essential for parasite growth and development. Inhibitors of both enzymes are lethal to P. falciparum in culture and kill the murine malaria P. chabaudi in vivo. Recent biochemical, structural and functional studies provide the substrate specificity and mechanistic binding data needed to guide the development of more potent anti-malarial drugs. Together with biological studies, these data form the rationale for choosing PfM1AAP and PfM17LAP as targets for anti-malarial development.

Original language	English
Pages (from-to)	53-61
Number of pages	9
Journal	Trends in Biochemical Sciences
Volume	35
Issue number	1
DOIs	https://doi.org/10.1016/j.tibs.2009.08.004
Publication status	Published - Jan 2010
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.tibs.2009.08.004

Cite this

Skinner-Adams, T. S., Stack, C. M., Trenholme, K. R., Brown, C. L., Grembecka, J., Lowther, J., Mucha, A., Drag, M., Kafarski, P., McGowan, S., Whisstock, J. C., Gardiner, D. L., & Dalton, J. P. (2010). Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials. Trends in Biochemical Sciences, 35(1), 53-61. https://doi.org/10.1016/j.tibs.2009.08.004

@article{23e458690f7a45a9933ad06d48e52f5f,

title = "Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials",

abstract = "The neutral aminopeptidases M1 alanyl aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) of the human malaria parasite Plasmodium falciparum are targets for the development of novel anti-malarial drugs. Although the functions of these enzymes remain unknown, they are believed to act in the terminal stages of haemoglobin degradation, generating amino acids essential for parasite growth and development. Inhibitors of both enzymes are lethal to P. falciparum in culture and kill the murine malaria P. chabaudi in vivo. Recent biochemical, structural and functional studies provide the substrate specificity and mechanistic binding data needed to guide the development of more potent anti-malarial drugs. Together with biological studies, these data form the rationale for choosing PfM1AAP and PfM17LAP as targets for anti-malarial development.",

author = "Skinner-Adams, \{Tina S.\} and Stack, \{Colin M.\} and Trenholme, \{Katharine R.\} and Brown, \{Chris L.\} and Jolanta Grembecka and Jonathan Lowther and Artur Mucha and Marcin Drag and Pawel Kafarski and Sheena McGowan and Whisstock, \{James C.\} and Gardiner, \{Donald L.\} and Dalton, \{John P.\}",

year = "2010",

month = jan,

doi = "10.1016/j.tibs.2009.08.004",

language = "English",

volume = "35",

pages = "53--61",

journal = "Trends in Biochemical Sciences",

issn = "0968-0004",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - Plasmodium falciparum neutral aminopeptidases

T2 - new targets for anti-malarials

AU - Skinner-Adams, Tina S.

AU - Stack, Colin M.

AU - Trenholme, Katharine R.

AU - Brown, Chris L.

AU - Grembecka, Jolanta

AU - Lowther, Jonathan

AU - Mucha, Artur

AU - Drag, Marcin

AU - Kafarski, Pawel

AU - McGowan, Sheena

AU - Whisstock, James C.

AU - Gardiner, Donald L.

AU - Dalton, John P.

PY - 2010/1

Y1 - 2010/1

N2 - The neutral aminopeptidases M1 alanyl aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) of the human malaria parasite Plasmodium falciparum are targets for the development of novel anti-malarial drugs. Although the functions of these enzymes remain unknown, they are believed to act in the terminal stages of haemoglobin degradation, generating amino acids essential for parasite growth and development. Inhibitors of both enzymes are lethal to P. falciparum in culture and kill the murine malaria P. chabaudi in vivo. Recent biochemical, structural and functional studies provide the substrate specificity and mechanistic binding data needed to guide the development of more potent anti-malarial drugs. Together with biological studies, these data form the rationale for choosing PfM1AAP and PfM17LAP as targets for anti-malarial development.

AB - The neutral aminopeptidases M1 alanyl aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) of the human malaria parasite Plasmodium falciparum are targets for the development of novel anti-malarial drugs. Although the functions of these enzymes remain unknown, they are believed to act in the terminal stages of haemoglobin degradation, generating amino acids essential for parasite growth and development. Inhibitors of both enzymes are lethal to P. falciparum in culture and kill the murine malaria P. chabaudi in vivo. Recent biochemical, structural and functional studies provide the substrate specificity and mechanistic binding data needed to guide the development of more potent anti-malarial drugs. Together with biological studies, these data form the rationale for choosing PfM1AAP and PfM17LAP as targets for anti-malarial development.

UR - https://www.scopus.com/pages/publications/74049107406

U2 - 10.1016/j.tibs.2009.08.004

DO - 10.1016/j.tibs.2009.08.004

M3 - Review article

C2 - 19796954

AN - SCOPUS:74049107406

SN - 0968-0004

VL - 35

SP - 53

EP - 61

JO - Trends in Biochemical Sciences

JF - Trends in Biochemical Sciences

IS - 1

ER -

Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this